



[Science](#)[Education](#)[Patient Care](#)

[Our Society](#)[Our Mission, Vision & Values](#)[EBMT Membership 2025](#)[Organisational Structure 2025](#)[Financial Highlights 2025](#)[EBMT Partners](#)

## Breadcrumb

1. [Home](#)

## Entity Print




Tobias Alexander  
ADWP Chair  
Germany

## Major achievements

Large randomised controlled trials have demonstrated the superiority of hematopoietic stem cell transplantation over standard-of-care therapies in systemic sclerosis and multiple sclerosis, which are now considered standard indications (Greco R et al., *BMT* 2025) and endorsed by their respective international societies (Del Galdo et al., *Ann Rheum Dis.* 2024) and ECTRIMS (Muraro et al., *Nat Rev Neurol.*

2025). The EBMT Autoimmune Diseases Working Party (ADWP) has been central to development of these approaches. Currently, 4839 patients have been reported to the EBMT registry (Fig. 1).



**Figure 1: Auto-HSCT cases reported to the EBMT Registry**

Meanwhile, CAR-T cell therapies are emerging as therapeutic alternatives with curative potential. In this context, the ADWP was central in developing expert-based position statement and clinical practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee on **innovative cellular therapies for ADs** (Greco et al, *EClinicalMedicine*. 2024).

Recent achievements from our Working Party include a paper on **best practice recommendations for HSCT in rheumatologic indications** (Alexander T et al., BMT 2025). In addition, our WP was central in providing a **position paper for the use of HSCT in multiple sclerosis** (Muraro P et al., *Nat Rev Neurol* 2025) and we provided a **review on HSCT in aggressive multiple sclerosis** (Boffa G et al., *Mult Scler* 2025). Furthermore, a large retrospective analysis investigated the optimal conditioning regimen in MS (Greco R et al., BMT 2025), and we defined **relapse criteria in patients with systemic sclerosis treated with HSCT** (Del Papa N et al., BMT 2025).

The ADWP is dedicated to promoting clinical activities, teaching and translational research on HCT together with innovative cellular therapies as AD treatment. We continued to expand the evidence-base and support best-practice with studies and guidelines, including significant collaborative outputs with the EBMT Working Parties, JACIE, Trainee Committee, Patient Advocacy Committee and Nurses Group. Education is key in the ADWP activities, including an educational meeting on “Advancements in cellular therapy for Autoimmune Diseases and Chronic Haematological Malignancies” held in Rome, and a harmonisation workshop on recommendations for CAR-T in rheumatic diseases that took place in Paris 2025.



Educational Meeting "Advancements in cellular therapy for Autoimmune Diseases and Chronic Haematological Malignancies"  
18-20 September 2025, Rome, Italy

## Principal research studies

[CAR-T Cell Therapy in Autoimmune Diseases as Concomitant or Main Indication: a 2-step Joint Study on behalf of EBMT ADWP and CTIWP](#)

[Study type](#)

[Closed Survey/Study](#)

[Diseases](#)

[Auto immune disorders](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

Type of treatment

CAR T

Principal investigator

Raffaella Greco

Autoimmune and autoinflammatory complications after CAR-T cell therapy - a joint study on behalf of the EBMT - ADWP, CTIWP and TCWP

Study type

Retrospective Studies

Diseases

Acute Lymphatic Leukaemia (ALL)

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Non-Hodgkin's Lymphoma (NHL)

Group

GoCART Coalition

Autoimmune Diseases Working Party (ADWP)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Complications Working Party (CWP)

Type of treatment

CAR T

Principal investigator

Matteo Doglio

Incidence and outcome of CMV and EBV reactivations after autologous HSCT for autoimmune diseases: a retrospective survey from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Study type

Retrospective Studies

Diseases

Auto immune disorders

Group

Autoimmune Diseases Working Party (ADWP)

Type of treatment

-

Principal investigator

Tobias Alexander

Outcomes of HSCT for autoimmune cytopenias (AIC): a Retrospective Registry Study from the Autoimmune Diseases Working Party (ADWP) and the Paediatric Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Study type

Retrospective Studies

Diseases

Auto immune disorders

Group

Autoimmune Diseases Working Party (ADWP)

Paediatric Diseases Working Party (PDWP)

Type of treatment

-

Principal investigator

Nichola Cooper

Observational Study in Multiple Sclerosis patients treated with autologous hematopoietic stem cell Transplantation (OMST)

Study type

Non-interventional Prospective Studies

Diseases

Auto immune disorders

Group

Autoimmune Diseases Working Party (ADWP)

Type of treatment

Autologous

Principal investigator

Riccardo Saccardi

## **Key publications**

2025

BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party

Group

Autoimmune Diseases Working Party (ADWP)

1st listed author

Raffaella Greco

Journal

Bone Marrow Transplant.

2025

[Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[Practice Harmonisation and Guidelines Committee](#)

[1st listed author](#)

[Tobias Alexander](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2025](#)

[Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow](#)

[Transplantation](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[1st listed author](#)

[Giacomo Boffa](#)

[Journal](#)

[Mult Scler.](#)

[2025](#)

[Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from](#)

[ECTRIMS and the EBMT](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[1st listed author](#)

[Paolo A Muraro](#)

[Journal](#)

[Nat Rev Neurol.](#)

[2025](#)

[Definition of relapse criteria in patients with rapidly progressive systemic sclerosis treated with autologous haemopoietic stem cell transplantation](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[1st listed author](#)

[Nicoletta Del Papa](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[See the full list of the ADWP 2025 publications](#)



## Indicators


	<b>2023</b>	<b>2024</b>	<b>2025</b>
<b>Impact factor</b>	54.39	76.30	<b>63.80</b>
<b>Oral presentations</b>	16	8	<b>10</b>
<b>Poster presentations</b>	4	1	<b>2</b>
<b>International educational events</b>	3	2	<b>2</b>

## Major educational events



[Event](#)

## **51st Annual Meeting of the FBMF**



[Event](#)

## **Advancements in cellular therapy for Autoimmune Diseases and Chronic Haematological Malignancies**

Sep 18, 2025 - Sep 20, 2025 / Rome, Italy

Discover more

### **Webinars and e-courses**

HSCT in Autoimmune Diseases E-Course

Panel Discussion: Autologous HSCT in Multiple Sclerosis

VISIT THE ADWP WEBPAGE